

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) ~~The use of hyaluronic acid in crosslinked form for the production of a composition~~ A method for preventing or treating an inflammatory skin or mucous membrane diseases ~~disease~~, comprising administering to a subject in need thereof an effective amount of hyaluronic acid in crosslinked form.

2. (Currently Amended) ~~The use as claimed in claim 1, characterized in that a composition for~~ A method according to claim 1, wherein administering is by local administration is produced.

3. (Currently Amended) ~~The use as claimed in claim 1, characterized in that a composition for~~ A method according to claim 1, wherein administering is by intradermal administration, for by administration to the border of the dermoepithelial transition or for by topical administration is produced.

4. (Currently Amended) ~~The use as claimed Claim 1, characterized in that~~ A method according to claim 1, wherein the degree of crosslinking is in the range from 0.1% to 10%.

5. (Currently Amended) ~~The use as claimed in Claim 1, characterized in that~~ A method according to claim 1, wherein the crosslinked hyaluronic acid is present in a mixture with uncrosslinked hyaluronic acid.

6. (Currently Amended) ~~The use as claimed in claim 5, characterized in that~~ A method according to claim 5, wherein the uncrosslinked hyaluronic acid is selected from

(i) long-chain hyaluronic acid having an average molecular weight (weight-average) of at least 200 kD, or and

(ii) short-chain hyaluronic acid having an average molecular weight (weight-average) up to 50 kD, ~~or mixtures thereof.~~

(iii) a mixture thereof.

7. (Currently Amended) ~~The use as claimed in Claim 1, characterized in~~  
~~that the~~ A method according to claim 1, wherein the hyaluronic acid is in a composition  
~~furthermore contains~~ which contains an inhibitor of hyaluronic acid degradation.

8. (Currently Amended) ~~The use as claimed in claim 9, characterized in~~  
~~that~~ A method according to claim 7, wherein the inhibitor of hyaluronic acid degradation is  
selected from heparin, indomethacin, ~~salicylates, free radical traps, such as a salicylate, a free~~  
~~radical trap, or~~ vitamin A, C or E, and ~~mixtures~~ or a mixture thereof.

9. (Currently Amended) ~~The use as claimed in Claim 1, characterized in~~  
~~that~~ A method according to claim 1, wherein the hyaluronic acid is present as an injectable  
preparation, ointment, cream, lotion, gel, spray, tincture, shampoo, occlusive film, powder or  
inhalable preparation.

10. (Currently Amended) ~~The use as claimed in Claim 1, characterized in~~  
~~that the~~ A method according to claim 1, wherein the hyaluronic acid is in a composition  
~~furthermore~~ which contains another a further glycosaminoglycan in crosslinked or  
uncrosslinked form.

11. (Currently Amended) ~~The use as claimed in Claim 1, characterized in~~  
~~that~~ A method according to claim 1, wherein the inflammatory skin or mucous membrane  
disease is selected from atopic dermatitis, ~~eezemas, such as eczema, seborrheic and or~~  
microbial ~~eezemas~~ eczema, pruritus, prurigo, urticaria, red lichen, psoriasis, ~~such as psoriasis~~  
vulgaris, vitiligo, a viral skin diseases disease which lead ~~leads~~ to wart formation, ~~such as~~  
verruca vulgaris, ~~or~~ Condylomata acuminata, rosacea, perioral dermatitis, acne, ~~such as acne~~  
vulgaris, ~~or~~ acne conglobata, a polypous mucous membrane diseases disease, ~~such as nasal~~  
polyposis, and an inflammatory intestinal diseases disease, a chronic or acute ulcerations  
ulceration of the skin, aphthae and ~~or~~ mycoses.

12. (Currently Amended) ~~The use as claimed in Claim 1 in~~ A method  
according to claim 1, wherein the subject is a human-medicine.

13. (Currently Amended) ~~The use as claimed in Claim 1 in~~ A method according to claim 1, wherein the subject is a veterinary medicine patient.

14. (Currently Amended) ~~A process for preventing or treating and according to claim 1, which is for treating an inflammatory skin or mucous membrane disease, characterized in that a preparation is administered to a subject to be treated, which contains hyaluronic acid in crosslinked form in an amount adequate for treating the disease.~~

15. (Currently Amended) ~~The use of hyaluronic acid in crosslinked form for the production of a composition~~ A method for preventing or treating an inflammatory diseases disease of the eye, comprising administering to a subject in need thereof an effective amount of hyaluronic acid in crosslinked form.

16. (Currently Amended) ~~The use as claimed in claim 15~~ A method according to claim 15, which is for preventing or treating an inflammatory diseases disease of the conjunctiva or cornea.

17. (Currently Amended) ~~The use as claimed in claim 15~~ A method according to claim 15, which is for preventing or treating after-cataract or inflammation of the conjunctiva.

18. (Currently Amended) ~~The use as claimed in Claim 15, characterized in that~~ A method according to claim 15, wherein the crosslinked hyaluronic acid is present in a mixture with uncrosslinked hyaluronic acid.

19. (Currently Amended) ~~The use as claimed in Claim 15, characterized in that the~~ A method according to claim 15, wherein the hyaluronic acid is in a composition furthermore which contains another a further glycos-aminoglycan in crosslinked or uncrosslinked form.

20. (Currently Amended) ~~The use of a mixture of crosslinked and uncrosslinked hyaluronic acid for the production of a cosmetic or pharmaceutical composition~~ A

method for treating skin or soft tissue defects and skin wrinkles comprising administering to a subject in need thereof an effective amount of hyaluronic acid in crosslinked form.

21. (Currently Amended) ~~The use as claimed in claim 20, characterized in~~  
~~that the~~ A method according to claim 20, wherein the hyaluronic acid is in a composition  
~~furthermore~~ which contains ~~another~~ a further glycos-aminoglycan in crosslinked or  
uncrosslinked form.